• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pan-cancer analysis of mutations as biomarkers for immunotherapy outcomes.作为免疫治疗结果生物标志物的突变的泛癌分析。
Ann Transl Med. 2020 Feb;8(4):141. doi: 10.21037/atm.2019.11.52.
2
Systematic Identification of Multi Omics-based Biomarkers in Mutated TCGA Lung Adenocarcinoma.基于多组学的TCGA肺腺癌突变生物标志物的系统鉴定
J Cancer. 2019 Nov 1;10(27):6813-6821. doi: 10.7150/jca.35489. eCollection 2019.
3
Clinical and Pathological Characteristics of - and -Mutated Non-Small Cell Lung Carcinoma (NSCLC).伴有 - 和 - 基因突变的非小细胞肺癌（NSCLC）的临床和病理特征。
Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3.
4
Somatic mutations of the KEAP1 gene in common solid cancers.常见实体瘤中 KEAP1 基因的体细胞突变。
Histopathology. 2012 May;60(6):943-52. doi: 10.1111/j.1365-2559.2012.04178.x. Epub 2012 Feb 20.
5
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.KEAP1/NRF2和TP53突变在肺鳞状细胞癌发生发展及放射抗性中的作用
Cancer Discov. 2017 Jan;7(1):86-101. doi: 10.1158/2159-8290.CD-16-0127. Epub 2016 Sep 23.
6
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.KEAP1/NFE2L2/CUL3 突变对 EGFR 突变型非小细胞肺癌患者接受 EGFR 酪氨酸激酶抑制剂治疗反应持续时间的影响。
Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.
7
KEAP1/NRF2 signaling pathway mutations in cervical cancer.宫颈癌中 KEAP1/NRF2 信号通路的突变。
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4458-4466. doi: 10.26355/eurrev_201807_15497.
8
Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.KEAP1-NRF2-CUL3 轴调控的基因表达谱与头颈部鳞状细胞癌的不良预后相关。
BMC Cancer. 2018 Jan 6;18(1):46. doi: 10.1186/s12885-017-3907-z.
9
Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.KEAP1 和 NRF2 基因突变和多态性与子宫内膜样腺癌生存的关系。
Int J Gynecol Cancer. 2011 Nov;21(8):1428-35. doi: 10.1097/IGC.0b013e31822d0eb2.
10
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.选择最佳一线治疗方案：无可操作致癌驱动因素的非小细胞肺癌
Lung Cancer Manag. 2020 Jul 24;9(3):LMT36. doi: 10.2217/lmt-2020-0003.

引用本文的文献

1
Novel Immune Modulatory Agents in the Treatment of Non-small Cell Lung Cancer.新型免疫调节药物治疗非小细胞肺癌
Cancer Treat Res. 2025;129:157-172. doi: 10.1007/978-3-031-97242-3_8.
2
Nrf2 hyperactivation as a driver of radiotherapy resistance and suppressed anti-tumor immunity in head and neck squamous cell carcinoma.Nrf2过度激活作为头颈部鳞状细胞癌放疗抵抗和抗肿瘤免疫抑制的驱动因素。
Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-0112.
3
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?KRAS 突变型癌症中的精准免疫调节：拼图的最后一块？
J Exp Clin Cancer Res. 2025 Jul 3;44(1):189. doi: 10.1186/s13046-025-03444-1.
4
Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis.kelch样ECH相关蛋白1/核因子红细胞2相关因子2通路及其在肺癌发生中与癌基因的相互作用
J Cancer Prev. 2024 Dec 30;29(4):89-98. doi: 10.15430/JCP.24.021.
5
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.恶性实体瘤中检查点抑制剂的预测生物标志物和耐药机制。
Int J Mol Sci. 2024 Sep 6;25(17):9659. doi: 10.3390/ijms25179659.
6
Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer.联合策略克服非小细胞肺癌治疗中对检查点抑制剂的耐药性
Cancers (Basel). 2024 Aug 22;16(16):2919. doi: 10.3390/cancers16162919.
7
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer.晚期非小细胞肺癌患者对一线PD-1阻断联合化疗反应的基因组相关性
Chin Med J (Engl). 2024 Aug 21;137(18):2213-22. doi: 10.1097/CM9.0000000000003094.
8
Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.多组学和人工智能预测非小细胞肺癌患者免疫治疗的临床结局。
Clin Exp Med. 2024 Mar 30;24(1):60. doi: 10.1007/s10238-024-01324-0.
9
-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.- 突变肺癌削弱抗肿瘤免疫并促进 M2 样巨噬细胞表型。
Int J Mol Sci. 2024 Mar 20;25(6):3510. doi: 10.3390/ijms25063510.
10
Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的基因特征及治疗策略进展
Front Med (Lausanne). 2024 Feb 27;11:1326426. doi: 10.3389/fmed.2024.1326426. eCollection 2024.

本文引用的文献

1
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.中国肺鳞癌的基因组图谱及其与肿瘤突变负荷、PD-L1 表达和免疫细胞浸润的相关性。
J Hematol Oncol. 2019 Jul 12;12(1):75. doi: 10.1186/s13045-019-0762-1.
2
Genomic correlates of response to immune checkpoint blockade.免疫检查点阻断治疗反应的基因组相关性。
Nat Med. 2019 Mar;25(3):389-402. doi: 10.1038/s41591-019-0382-x. Epub 2019 Mar 6.
3
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
4
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境（TIME）以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
5
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.TIMER：用于肿瘤浸润免疫细胞综合分析的网络服务器。
Cancer Res. 2017 Nov 1;77(21):e108-e110. doi: 10.1158/0008-5472.CAN-17-0307.
6
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
7
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.KEAP1/NRF2和TP53突变在肺鳞状细胞癌发生发展及放射抗性中的作用
Cancer Discov. 2017 Jan;7(1):86-101. doi: 10.1158/2159-8290.CD-16-0127. Epub 2016 Sep 23.
8
Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.KEAP1/NRF2信号对非小细胞肺癌中铂敏感性的影响
J Hematol Oncol. 2016 Sep 6;9(1):83. doi: 10.1186/s13045-016-0311-0.
9
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.PD-1/PD-L1 抑制剂在非小细胞肺癌临床应用中的生物标志物：综述。
JAMA Oncol. 2016 Sep 1;2(9):1217-22. doi: 10.1001/jamaoncol.2016.0639.
10
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.利用 cBioPortal 进行复杂癌症基因组学和临床特征的综合分析
Sci Signal. 2013 Apr 2;6(269):pl1. doi: 10.1126/scisignal.2004088.

Pan-cancer analysis of mutations as biomarkers for immunotherapy outcomes.

作者信息

Chen Xiaoxia, Su Chunxia, Ren Shengxiang, Zhou Caicun, Jiang Tao

机构信息

Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.

出版信息

Ann Transl Med. 2020 Feb;8(4):141. doi: 10.21037/atm.2019.11.52.

DOI:10.21037/atm.2019.11.52
PMID:32175433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7048975/
Abstract
摘要